FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2083089310> ?p ?o ?g. }

• W2083089310 endingPage "35" @default.
• W2083089310 startingPage "23" @default.
• W2083089310 abstract "Acute leukemia is the most common form of childhood cancer and is the primary cause of cancer-related mortality in children. In the United approximately 3250 cases are diagnosed annually in children and adolescents younger than 20 years, of whom 2400 have acute lymphoblastic leukemia (ALL). Treatment results in childhood ALL continue to improve, and the expected current cure rates approach 75 to 80% of all children with ALL, including T-ALL and mature B-cell ALL, the two variants that, not too long ago, had a considerably poorer prognosis compared with the common form of BpALL. The most significant new development in the past 2 years has been the development of further evidence for fetal origin of childhood leukemias, and additional evidence to support the notion that postnatal events modulating the events of immune-mediated elimination of these leukemic clones play a major role in the eventual development of clinical disease. Other epidemiologic developments include (1) increased appreciation of the role of drug-metabolizing enzymes, both in determining the predisposition to leukemia and response to therapy; and (2) both clinical observations and gene expression studies seeming to identify a new approach to the evaluation and treatment of children with MLL (11q23) rearrangements. A most remarkable new development in the induction therapy of childhood leukemia and lymphoma in the United States is the use of urate oxidase for prevention of tumor lysis syndrome and the associated uric acid nephropathy. Drug resistance, determined either on leukemic blast cells in vitro or by studies of MRD, is being looked at critically in an effort to improve the treatment results further. Consolidation with HDMTX has gained wider popularity with the realization that effective CNS prophylaxis can be achieved with intrathecal therapy plus HDMTX for consolidation. In contrast to ALL, the progress in the therapy of acute myeloid leukemia (AML) lags behind, with cure rates of approximately 40 to 50%. There is no convincing evidence for substitution of daunorubicin with other anthracyclines, nor evidence for using high-dose cytarabine during induction in childhood AML. Rather, a 3 + 10 regimen with total daunorubicin 180 mg/m2 and cytarabine 100 to 200 mg/2 for 10 days appears to yield the best results. The most important component of the postremission chemotherapy continues to be several courses of high-dose cytarabine. The results from the MRC 10, LAME 89/91 studies and the recent BFM 93 trial with high-dose cytarabine and mitoxantrone suggest that there may be some benefit to including this combination in the postremission phase of AML. Despite these improvements in chemotherapy, allogeneic BMT from a matched family donor remains the best option for most patients (excluding Down syndrome, APL, and possibly those with inv16). Newer prognostic markers of interest include FLT3/ITD and minimal residual disease at the end of induction therapy." @default.
• W2083089310 created "2016-06-24" @default.
• W2083089310 creator A5062366315 @default.
• W2083089310 date "2003-01-01" @default.
• W2083089310 modified "2023-10-13" @default.
• W2083089310 title "Recent advances in pediatric acute lymphoblastic and myeloid leukemia" @default.
• W2083089310 cites W1143126211 @default.
• W2083089310 cites W116308216 @default.
• W2083089310 cites W1492445977 @default.
• W2083089310 cites W1509637701 @default.
• W2083089310 cites W1520363931 @default.
• W2083089310 cites W152381011 @default.
• W2083089310 cites W1534965621 @default.
• W2083089310 cites W1576233656 @default.
• W2083089310 cites W1620449961 @default.
• W2083089310 cites W1775087301 @default.
• W2083089310 cites W1835750525 @default.
• W2083089310 cites W1847612791 @default.
• W2083089310 cites W1850914599 @default.
• W2083089310 cites W1863587549 @default.
• W2083089310 cites W1864995945 @default.
• W2083089310 cites W1893581600 @default.
• W2083089310 cites W1919687592 @default.
• W2083089310 cites W1925208328 @default.
• W2083089310 cites W1968487471 @default.
• W2083089310 cites W1972935214 @default.
• W2083089310 cites W1974315565 @default.
• W2083089310 cites W1978072477 @default.
• W2083089310 cites W1984183164 @default.
• W2083089310 cites W1984620288 @default.
• W2083089310 cites W1986846017 @default.
• W2083089310 cites W1987122687 @default.
• W2083089310 cites W1987136467 @default.
• W2083089310 cites W1987588179 @default.
• W2083089310 cites W1993481049 @default.
• W2083089310 cites W2000278497 @default.
• W2083089310 cites W2001584634 @default.
• W2083089310 cites W2004153775 @default.
• W2083089310 cites W2005956568 @default.
• W2083089310 cites W2008896686 @default.
• W2083089310 cites W2013051826 @default.
• W2083089310 cites W2014831634 @default.
• W2083089310 cites W2015440945 @default.
• W2083089310 cites W2016442087 @default.
• W2083089310 cites W2019063768 @default.
• W2083089310 cites W2027003150 @default.
• W2083089310 cites W2033062649 @default.
• W2083089310 cites W2034472402 @default.
• W2083089310 cites W2036060397 @default.
• W2083089310 cites W2039677781 @default.
• W2083089310 cites W2040336044 @default.
• W2083089310 cites W2041284044 @default.
• W2083089310 cites W2042129979 @default.
• W2083089310 cites W2043415837 @default.
• W2083089310 cites W2045316827 @default.
• W2083089310 cites W2045394616 @default.
• W2083089310 cites W2050863148 @default.
• W2083089310 cites W2058710761 @default.
• W2083089310 cites W2059972525 @default.
• W2083089310 cites W2060927981 @default.
• W2083089310 cites W2067020831 @default.
• W2083089310 cites W2068619849 @default.
• W2083089310 cites W2070173503 @default.
• W2083089310 cites W2070767183 @default.
• W2083089310 cites W2071337636 @default.
• W2083089310 cites W2079214256 @default.
• W2083089310 cites W2081495071 @default.
• W2083089310 cites W2086404440 @default.
• W2083089310 cites W2087182733 @default.
• W2083089310 cites W2093206858 @default.
• W2083089310 cites W2095026923 @default.
• W2083089310 cites W2095405591 @default.
• W2083089310 cites W2098854099 @default.
• W2083089310 cites W2108253137 @default.
• W2083089310 cites W2113911127 @default.
• W2083089310 cites W2118457944 @default.
• W2083089310 cites W2119685895 @default.
• W2083089310 cites W2123554519 @default.
• W2083089310 cites W2126869110 @default.
• W2083089310 cites W2126908771 @default.
• W2083089310 cites W2130714065 @default.
• W2083089310 cites W2132912591 @default.
• W2083089310 cites W2138218344 @default.
• W2083089310 cites W2143362267 @default.
• W2083089310 cites W2145956223 @default.
• W2083089310 cites W2154212069 @default.
• W2083089310 cites W2156073127 @default.
• W2083089310 cites W2159289068 @default.
• W2083089310 cites W2164840791 @default.
• W2083089310 cites W2167654982 @default.
• W2083089310 cites W2178680838 @default.
• W2083089310 cites W2210954273 @default.
• W2083089310 cites W2241310562 @default.
• W2083089310 cites W2242156109 @default.
• W2083089310 cites W2315152253 @default.
• W2083089310 cites W2317674375 @default.
• W2083089310 cites W2318310351 @default.
• W2083089310 cites W2320844704 @default.

• next